Finding multiple target optimal intervention in disease-related molecular network

Molecular Systems Biology

Volumn 4, Issue , 2008, Pages

  Yang, Kun ^a,b   Bai, Hongjun ^a,b   Ouyang, Qi ^b   Lai, Luhua ^a,b   Tang, Chao ^b,c  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammatory; Arachidonic acid metabolic network; Drug efficacy prediction; Multiple target drug design; Network based drug design

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; LICOFELONE; MELOXICAM; NAPROXEN; NIMESULIDE; PARACETAMOL; ROFECOXIB;

ALGORITHM; ARTICLE; DRUG EFFICACY; DRUG TARGETING; HUMAN; INTERVENTION STUDY; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; DRUG DESIGN; DRUG THERAPY; GENERAL ASPECTS OF DISEASE; PHARMACOLOGY;

ALGORITHMS; DISEASE; DRUG DESIGN; DRUG THERAPY; HUMANS; PHARMACOLOGY;

EID: 55549101279     PISSN: 17444292     EISSN: 17444292     Source Type: Journal    
DOI: 10.1038/msb.2008.60     Document Type: Article

References (63)

1. Abbate R, Gori AM, Pinto S, Attanasio M, Paniccia R, Coppo M, Castellani S, Giusti B, Boddi M, Neri Serneri GG (1990) Cyclooxygenase and lipoxygenase metabolite synthesis by polymorphonuclear neutrophils: in vitro effect of dipyrone. Prostaglandins Leukot Essent Fatty Acids 41: 89-93
2. Ahren B (2008) Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 4: 383-394
3. Alvaro-Gracia JM (2004) Licofelone - clinical update on a novel LOX/ COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford) 43 (Suppl. 1): i21-i25
4. Ambegaonkar A, Livengood K, Craig T, Day D (2004) Predicting the risk for gastrointestinal toxicity in patients taking NSAIDs: the Gastrointestinal Toxicity Survey. Adv Ther 21: 288-300
5. Anderson MW, Crutchley DJ, Tainer BE, Eling TE (1978) Kinetic studies on the conversion of prostaglandin endoperoxide PGH2 by thromboxane synthase. Prostaglandins 16: 563-570
6. Araujo RP, Liotta LA, Petricoin EF (2007) Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov 6: 871-880
7. Arellano FM (2005) The withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 14: 213-217
8. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR (2003) Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 91: 667-672
9. Bias P, Buchner A, Klesser B, Laufer S (2004) The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 99: 611-618
10. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT (2003) Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100: 7977-7982
11. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G et al (2004) A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 6: 97-105
12. Brooks P (1998) Use and benefits of nonsteroidal anti-inflammatory drugs. Am J Med 104: 9S-13S; discussion 21S-22S
13. Camacho M, Lopez-Belmonte J, Vila L (1998) Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ Res 83: 353-365
14. Csermely P, Agoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26: 178-182
15. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 104: 1777-1782
16. Fahmi H (2004) mPGES-1 as a novel target for arthritis. Curr Opin Rheumatol 16: 623-627
17. Food and Drug Administration (2004) Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. FDA White Paper (http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf)
18. Frantz S (2005) Drug discovery: playing dirty. Nature 437: 942-943
19. Ganter B, Tugendreich S, Pearson CI, Ayanoglu E, Baumhueter S, Bostian KA, Brady L, Browne LJ, Calvin JT, Day GJ, Breckenridge N, Dunlea S, Eynon BP, Furness LM, Ferng J, Fielden MR, Fujimoto SY, Gong L, Hu C, Idury R et al (2005) Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 119: 219-244
20. Gupta EK, Ito MK (2002) Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis 4: 124-137
21. Haeggstrom JZ (2004) Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J Biol Chem 279: 50639-50642
22. Honn KV, Cicone B, Skoff A (1981) Prostacyclin: a potent antimetastatic agent. Science 212: 1270-1272
23. Hopkins AL, Mason JS, Overington JP (2006) Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16: 127-136
24. Hwang WC, Zhang A, Ramanathan M (2008) Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery. Clin Pharmacol Ther (advance online publication, 9 July 2008; doi:10.1038/clpt.2008.129)
25. Ivanov AI, Romanovsky AA (2004) Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front Biosci 9: 1977-1993
26. Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6: 202-210
27. Kiviniemi H, Ramo J, Stahlberg M, Laitinen S, Jalovaara P, Viinikka L, Kairaluoma M (1987) Prostacyclin and thromboxane in acute hemorrhagic pancreatitis in dogs. J Surg Res 42: 232-236
28. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S (2004) Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114: 784-794
29. Korcsmaros T, Szalay MS, Bode C, Kovacs IA, Csermely P (2007) How to design multi-target drugstarget search options in cellular networks. Expert Opin Drug Discov 2: 799-808
30. Kusmak JM (2005) COX-2 inhibitors and the risk for cardiovascular events: a re-evaluation of the data and proposed mechanisms. SDJ Med 58: 269-272
31. Kyrle PA, Minar E, Brenner B, Eichler HG, Heistinger M, Marosi L, Lechner K (1989) Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis - effect of low-dose aspirin. Thromb Haemost 61: 374-377
32. Larder BA, Kemp SD, Harrigan PR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699
33. Lehar J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, Short III GF, Giusti LC, Nolan GP, Magid OA, Lee MS, Borisy AA, Stockwell BR, Keith CT (2007) Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 3: 80
34. Lindsay MA (2003) Target discovery. Nat Rev Drug Discov 2: 831-838
35. Martin C, Varner MW, Branch DW, Rodgers G, Mitchell MD (1996) Dose-related effects of low dose aspirin on hemostasis parameters and prostacyclin/thromboxane ratios in late pregnancy. Prostaglandins 51: 321-330
36. Nelson HS (2001) Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 107: 398-416
37. Palsson BO, Lee ID (1993) Model complexity has a significant effect on the numerical value and interpretation of metabolic sensitivity coefficients. J Theor Biol 161: 299-315
38. Pant D, Ghosh A (2005) Automated oncogene detection in complex protein networks with applications to the MAPK signal transduction pathway. Biophys Chem 113: 275-288
39. Patrono C, Patrignani P, Garcia Rodriguez LA (2001) Cyclooxygenase- selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108: 7-13
40. Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, Surendranath V, Niranjan V, Muthusamy B, Gandhi TK, Gronborg M, Ibarrola N, Deshpande N, Shanker K, Shivashankar HN, Rashmi BP, Ramya MA, Zhao Z, Chandrika KN, Padma N, Harsha HC et al (2003) Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 13: 2363-2371
41. Rahman SZ, Khan RA (2004) Is nimesulide safe in a cardiovascular- compromised patient. Indian J Pharmacol 36: 252-253
42. Rainsford KD (1993) Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage. Agents Actions 39 (Spec no.): C24-C26
43. Rajasethupathy P, Vayttaden SJ, Bhalla US (2005) Systems modeling: a pathway to drug discovery. Curr Opin Chem Biol 9: 400-406
44. Rotondo S, Dell'Elba G, Manarini S, Cerletti C, Evangelista V (2006) The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit. Eur J Pharmacol 546: 95-101
45. Sams-Dodd F (2005) Target-based drug discovery: is something wrong? Drug Discov Today 10: 139-147
46. Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224
47. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G (2002) Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 20: 370-375
48. Shak S, Goldstein IM (1984) Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. J Biol Chem 259: 10181-10187
49. Sharom JR, Bellows DS, Tyers M (2004) From large networks to small molecules. Curr Opin Chem Biol 8: 81-90
50. Shastry BS (2005) Genetic diversity and new therapeutic concepts. J Hum Genet 50: 321-328
51. Simmons PM, Salmon JA, Moncada S (1983) The release of leukotriene B4 during experimental inflammation. Biochem Pharmacol 32: 1353-1359
52. Singh D (2004) Merck withdraws arthritis drug worldwide. BMJ 329: 816
53. Smith JB, Araki H, Lefer AM (1980) Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation 62: V19-V25
54. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080
55. Suleyman H, Demircan B, Karagoz Y (2007) Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 59: 247-258
56. Sun B, Li Z (2000) NSAID induced gastric mucosal damage and its prevention in rats. World Chin J Digest 8: 271-275
57. Sung MH, Simon R (2004) In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics. Mol Pharmacol 66: 70-75
58. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40: 1109-1120
59. Vidal C, Gomez-Hernandez A, Sanchez-Galan E, Gonzalez A, Ortega L, Gomez-Gerique JA, Tunon J, Egido J (2007) Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther 320: 108-116
60. Wang D, Wang M, Cheng Y, Fitzgerald GA (2005) Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 5: 204-210
61. Xiao H, Yang CS (2008) Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer 123: 983-990
62. Yang K, Ma W, Liang H, Ouyang Q, Tang C, Lai L (2007) Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput Biol 3: e55
63. Zimmermann GR, Lehar J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42